Hypertension  by Dustan, Harriet P.
Journal of the American College of Cardiology 
© 2000 by the American College of Caxdiology 
Published by Elsevier Science Inc. 
Vol. 35, No. 5, Suppl B 
ISSN 0735-1097/00/$20.00 
PII S0735-1097(99)00069-8 
Hypertension 
Harriet P. Dustan, MD, FACC 
Burlington, Vermont 
This brief review recounts how systolic hypertension came 
to be recognized as an important determinant of  cardiovas- 
cular disease, beginning with the publication of a Framing- 
ham data-based article in the American Journal of Cardiology 
in April 1971. 
Systolic Versus Diastolic 
Blood Pressure and 
Risk of Coronary Heart Disease 
The Framingham Study 
by Kannel, Gordon and Schwartz (1) 
ABSTRACT 
A comparison of the contribution of systolic versus diastolic blood 
pressure to risk of coronary heart disease and the role of mean 
arterial pulse pressure and systolic lability have been examined 
prospectively in 5,127 men and women during 14 years of 
biennial follow-up studies. 
Similar gradients of risk of subsequent coronary heart disease 
were obsowed wbether persons were classified by their systolic or 
diastolic pressure, and no "safe" or crRical level could be 
identified. Assessment of the net effect of each, employing 
discriminant analysis, indicated a stronger association of systolic 
than diastolic pressure with risk of coronary heart disease. 
Neither the systolic and diastolic pressure measurements in
combination nor the pulse pressure and the mean artev'ial 
pressure measurements alone discriminated better than the 
systolic measurement alone. Systolic lability did not predict 
incidence of coronary heart disease independently of the associ- 
ated level of blood pressure. 
There was a trend of declining relative importance of'diastolic 
and a corresponding increase in the importance of systolic 
pressure with advancing age. Only in those under 45 was 
diastolic pressure predominant. The level of casually obtained 
blood pressure was a good predictor of coronary heart disease. 
The current practice of assessing the importance of blood pressure 
at all ages largely on the basis of diastolic pressure and the 
commonly held view concerning the innocuous nature of an 
elevated level of systolic pressure in the elderly requires reeval- 
uation. 
Originally pubfished inAmerican Journal of Cardiology, April 1971 
From the University of Vermont, College of Medicine, Burlington, Vermont. 
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SYSTOLIC HYPERTENSION AS A CV RISK FACTORB 
HAS IT FINALLY BEEN ACCEPTED? 
In 1971 Kannel, Gordon and Schwartz published a paper 
showing systolic blood pressure to be a better predictor of 
coronary heart disease than diastolic pressure (1). That 
50th Anniversary Historical Article 
INTRODUCTION 
In this edition of the Journal, we release the third in a series of 
reviews of influential articles that have been previously pub- 
fished in ACC journals, including the American Jom~al of 
Cardiology (from 1958 to 1982), and JACC (from 1983 to the 
present). The publication of these articles is only one aspect of 
the ACC's 50th anniversary commemoration, which highlights 
50 years of leadership in cardiovascular care and education. The 
articles are intended to encourage r flection on the remarkable 
progress made in cardiovascular medicine over time, as well as 
to acknowledge the amazing prescience of some earl), investi- 
gators in anticipating and, in many cases, later guiding devel- 
opments in their field. 
The working group responsible for selecting these articles and 
asking reviewers to write editorials solicited suggestions from 
the ACC's clinical committees and individual members. 
The group achieved consensus fairly easily', including whom the 
group should ask to prepare the accompanying editorials. We 
initially drew up a list of 14 general areas to cover in this series, 
but later found that there are several major areas of modern 
cardiology, prominently molecular cardiology, in which the 
truly landmark articles have, alas, not yet been published in 
JACC. Therefore, the working group decided not to categorize 
by subject, but instead, to concentrate on the most important 
articles. 
The working group, a task force of the Subcommittee for the 
Commemoration f the ACC 50th Anniversary, owes a great 
deal to Ms. May A. Roustom and the efficient and tireless taff 
at Heart House for facilitating this project. We also wish to 
thank all who suggested articles and, most important, the 
authors who prepared reviews for their willingness to contribute 
their time and wisdom. 
Influential ArtMes in JACC Working Group 
Sharon A. Hunt, M.D., F.A.C.C. 
Rick A. Nishimura, M.D., F.A.C.C. 
H.J.C. Swan, M.D., Ph.D., M.A.C.C. 
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paper was the beginning of a change in attitude towards 
systolic hypertension which for years had been considered 
physiologically insignificant. 
Now, 28 years later, systolic pressure is given more 
emphasis than diastolic pressure (2) and the importance 
of the latter is at times trivialized (3). Twenty-eight years 
seems a long time for a concept to become firmly 
established and one wonders why, particularly since the 
1971 paper was based on Framingham data which have 
formed the basis of most of our principles of preventive 
cardiology. This is not the first time hypertension has 
been slow to be accepted as a health problem and it seems 
to have chronic ill luck in that regard (ill luck for 
patients) of being slow in becoming accepted as an 
abnormality carrying significant risks for premature car- 
diovascular morbidity and mortality. Twenty-eight years 
may be a long time, but it is substantially less than the 59 
years from the 1913 report by Janeway of the fatal 
complications of hypertension (4) and the 1972 begin- 
nings of the National High Blood Pressure Education 
Program (NHBPEP) which successfully promoted hy- 
pertension as a major public health problem highly 
responsive to medical treatment. 
Between 1913 and 1972 lots of things happened which 
were finally responsible for putting hypertension on the 
hst of diseases that respond favorably to treatment and 
that doctors should treat. First, hypertension had to be 
recognized as a serious, though often symptomless, ill- 
ness. There were some long term follow-up reports, but 
the most compelling evidence came from insurance data. 
These were published in 1925 (5) and 1940 (6), but most 
doctors were not impressed. This lack of interest may 
have reflected a lack of effective treatment. The few 
doctors who did recognize hypertension as a serious 
public health problem looked for therapies and early 
treatments, which gave some relief to the few patients 
who received them, such as lumbodorsal sympathectomy, 
low sodium diets and pyrogen therapy. 
The breakthrough came in 1951 when drugs became 
available that were orally active and had long-term effec- 
tiveness. The patients that were treated at first were those 
with severe diastolic hypertension. Diastolic hypertension 
was the focus of attention because these people died young. 
Systolic hypertension received no real attention because it 
was found mostly in old people who, unlike today, were not 
expected to live long lives. Actually, systolic pressure was 
thought o increase as a natural process of aging so doctors 
simply disregarded it; it was the young and middle-aged 
people with severe diastolic hypertension that concerned 
them. 
Although the successful drug treatment of malignant 
hypertension was impressive to the few doctors respon- 
sible (7,8), it was the results of the VA Cooperative Trials 
that were decisive in changing public policy (9,10). They 
showed without question that treating diastolic blood 
pressures of 104 to 129 mm Hg protected against 
development of strokes, cardiac failure and worsening 
hypertension. These were the data that sparked evelop- 
ment of the NHBPEP which through a broad based 
public and professional education program has been 
responsible for striking decreases in deaths from strokes 
and heart attacks. 
All this time nobody but a few thought anything about 
systolic hypertension. Some had tried (11,13) going back as 
far as 1927 (11), but the data were disregarded; doctors 
were too preoccupied with the need to treat diastolic 
hypertension. 
By 1971 doctors had learned to respect data from the 
Framingham study. After all it had clearly delineated the 
many risk factors for coronary heart disease and doctors, 
with varying degrees of enthusiasm, were prescribing low 
fat diets, urging weight loss and using drugs to control 
diabetes and hyperlipidemia, dvising smoking cessation 
and treating hypertension. Yet, apparently as much as 
they respected the multiple risk factor basis for coronary 
heart disease, they were not ready to accept systolic 
hypertension as a better predictor of,coronary heart 
disease than diastolic hypertension. Also, the drugs 
available in the 1970s were thought not to be effective in 
lowering systolic blood pressure. 
Slowly a change in attitude came as systolic hyperten- 
sion was found to be more important han diastolic 
pressure in strokes, heart failure and peripheral vascular 
disease (14). Furthermore, a 1988 longitudinal study of 
the 317,871 men who had been screened for the Multiple 
Risk Factor Intervention Trial (15) confirmed the find- 
ings of the Framingham study. Thus, evidence support- 
ing systolic hypertension as an important determinant of 
cardiovascular disease became almost impossible to ig- 
nore. A sign of this change in attitude is the Fifth Report 
of the National Committee on Detection, Evaluation and 
Treatment of Hypertension (JNC 5) (16) which by 1993 
had included systolic blood pressure in the classification 
of blood pressure giving it equal billing with diastolic 
pressure. Another important report was that of the 
Systolic Hypertension i  the Elderly Program (SHEP) 
(17) which showed that systolic blood pressure could be 
decreased significantly by chlorthalidone and, if neces- 
sary, the addition of atenolol and that this reduction 
protected against strokes and other complications of 
hypertension. 
How are doctors responding to this challenge 28 years 
and much more evidence later? We do not know for sure, 
but we do know that 10 years ago New Jersey cardiologists 
did not treat isolated systolic hypertension as often as did 
internists and family physicians (18). But that was 10 years 
ago and one can hope that a cavalier attitude towards 
systolic hypertension has generally been discarded. 
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